The Macular Degeneration Foundation welcomes the Australian approval of Eylea® (aflibercept, VEGF Trap-Eye) by the TGA (Therapeutic Goods Administration) for the treatment of wet age-related macular degeneration (AMD).
This means the drug has been approved in Australia for safety (safe to use) and efficacy (effectiveness).
The Foundation looks forward to the drug being available in Australia as soon as possible.
Eylea is not yet subsidised by the Pharmaceutical Benefits Scheme (PBS).
The Foundation is working on behalf of clients to have the federal government add Eylea to the PBS as soon as possible and has already lodged a formal submission for this purpose.
Eylea is intended to treat the leaking blood vessels behind the retina that result in wet AMD.
8 March 2012